Collaborative Medicinal Development Enrolls First Patient In a Randomized, Placebo-Controlled Clinical Trial of CuATSM For The Treatment of Amyotrophic Lateral Sclerosis
CuATSM improves motor function and extends survival but is not tolerated at a high dose in SOD1G93A mice with a C57BL/6 background | Scientific Reports
New ALS drug slows disease progression in groundbreaking clinical trial
Blog: Phase 1 extension trial on CuATSM now enrolling in Australia | ALS Therapy Development Institute
MND Australia - Latest news on copper-ATSM The first clinical trial of copper-ATSM as a potential treatment option for MND will start in 2016. Cu-ATSM therapy was developed in Australia, the first-in-man
Blog: Copper Compound (CuATSM) Shows Promise in ALS Lab Studies | ALS Therapy Development Institute
Relationship between 18 F-FDG SUV roi and 62 Cu-ATSM SUV roi obtained... | Download Scientific Diagram
A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy - International Journal of Radiation Oncology, Biology, Physics
Breakthrough in motor neurone disease research gives hope | Pursuit by The University of Melbourne
CuATSM efficacy is independently replicated in a SOD1 mouse model of ALS while unmetallated ATSM therapy fails to reveal benefits - ScienceDirect
CuII(atsm) inhibits ferroptosis: Implications for treatment of neurodegenerative disease - Southon - 2020 - British Journal of Pharmacology - Wiley Online Library
A copper chaperone-mimetic polytherapy for SOD1-associated amyotrophic lateral sclerosis - preLights
First ALS Patient Enrolled in Phase 2/3 Trial of CuATSM
Neuroprotective effect of CuATSM on neurotoxin-induced motor neuron loss in an ALS mouse model - ScienceDirect
Motor neurone disease breakthrough: Patient trial shows impressive clinical results
MND in the news - CuATSM (copper ATSM)
CuATSM Compared With Placebo for Treatment of ALS/MND | Clinical Research Trial Listing ( Amyotrophic Lateral Sclerosis | Myelopathy | lou gehrig's disease | Amyotrophic Lateral Sclerosis (ALS) | Spinal Cord Disorders ) ( NCT04082832 )
CuATSM improves motor function and extends survival but is not tolerated at a high dose in SOD1G93A mice with a C57BL/6 background | Scientific Reports
Copper-64-diacetyl-bis(N4-methylthiosemicarbazone): An agent for radiotherapy | PNAS
Blog: Copper ATSM as a Potential Treatment for ALS | ALS Therapy Development Institute
CuATSM efficacy is independently replicated in a SOD1 mouse model of ALS while unmetallated ATSM therapy fails to reveal benefits - ScienceDirect
![Identification and quantitative structure–activity relationship assessment of trace chemical impurities contained in the therapeutic formulation of [64Cu]Cu-ATSM - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0969805122000129-ga1.jpg "Identification and quantitative structure–activity relationship assessment of trace chemical impurities contained in the therapeutic formulation of [64Cu]Cu-ATSM - ScienceDirect")
Identification and quantitative structure–activity relationship assessment of trace chemical impurities contained in the therapeutic formulation of [64Cu]Cu-ATSM - ScienceDirect
ALS Progression May Be Slowed With CuATSM Treatment, Trial Shows
CMD LLC wins AU$1 million grant award from FightMND
CuATSM efficacy is independently replicated in a SOD1 mouse model of ALS while unmetallated ATSM therapy fails to reveal benefits - ScienceDirect
